The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2014.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.
Chapter 4 provides a review of the leading Joint venture deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2014 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.
The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2014. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.
Key benefits Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal trends since 2014 Analysis of the structure of joint venture agreements with real life case studies Comprehensive listing of all joint venture deals since 2014, together with deal terms, value and press release Comprehensive access to actual joint venture contracts entered into by the world’s life science companies Insight into the terms included in a joint venture agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide.
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes: Trends in joint venture dealmaking in the biopharma industry since 2014 Analysis of joint venture deal structure Case studies of real-life joint venture deals Comprehensive listing of joint venture deals since 2014 Access to joint venture contract documents The leading joint venture deals by value since 2014 Most active joint venture dealmakers since 2014 The leading joint venture partnering resources
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology type
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How do milestone align with clinical stage development phases? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
The aptamers market valued at an estimated USD 151 million in 2021 and is projected to reach USD 342 million by 2026, at a CAGR of 17.7% during the forecast period. Growth of aptamers market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages...
Contract Small Molecule API Manufacturing Industry by the Numbers - 2021 Edition Summary This report is an updated version of the 2019 edition and characterizes the contract small molecule active pharmaceutical ingredient (API) manufacturing industry through a number of quantitative dimensions, including...
The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report. This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology, device and diagnostic sectors. Fully revised and updated, the report...
The global peptide synthesis market is projected to reach USD 730 million by 2026 USD 515 million in 2021, at a CAGR of 7.2% during the forecast period. Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced...
The global western blotting market is projected to reach USD 1.4 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 6.7% during the forecast period. Technological advancements, increasing government funding in the field of biomedical research, growing demand for personalized medicine, and the rising prevalence of HIV are the key factors...
The global chromatography resins market grew at a CAGR of around 7% during 2015-2020. Chromatography resins provide support to polysaccharide beads that are packed into a column. They are available with different purification efficiency, flow resistance and binding capacity. Some of the commonly utilized chromatography...
The global protein purification and isolation market exhibited moderate growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of around 8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
The cleanroom technology market is expected to reach US$ 8,356.97 million by 2028 from US$ 5,233.63 million in 2021; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028. A few factors such as increasing adoption in the biopharmaceuticals industry and technological advancements in cleanrooms are driving the growth of the market. However,...
The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.